GBS|CIDP Foundation International

Patients Who Use Medicines Made from Plasma Share How Their Lives Were Saved Thanks to Plasma Donors

KING OF PRUSSIA, PA — The GBS|CIDP Foundation International serves patients living with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and variants of the condition such as multifocal motor neuropathy …

Patients Who Use Medicines Made from Plasma Share How Their Lives Were Saved Thanks to Plasma Donors Read More


Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies …

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE Read More

Virpax Pharmaceuticals

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children

BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has acquired the exclusive worldwide rights from Nanomerics Ltd. to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of …

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children Read More

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the publication this week of results from the Company’s open-label Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy …

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel Read More